References
- Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol 1999; 128:8–14
- Cantor LB, Hoop J, Katz LJ, . Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25% suspension in patients with elevated intraocular pressure. Clin Ther 2001; 23:1032–39
- Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. Surv Ophthalmol 1996; 41 (Suppl 1) S39–47
- Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 2002; 11:119–26
- Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol 1999; 127:20–6
- Kim CY, Hong S, Seong GJ. Brimonidine 0.2% versus brimonidine purite 0.15% in Asian ocular hypertension. J Ocul Pharmacol Ther 2007; 23:481–6
- LeBlanc RP. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension, Brimonidine Study Group 2. Ophthalmology 1998; 105:1960–7
- Schuman JS, Horwitz B, Choplin NT, . A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol 1997; 115:847–52
- Melamed S, David R. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results, Brimonidine Study Group II. Clin Ther 2000; 22:103–11
- Lee DA, Gornbein J, Abrams C. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. Glaucoma Trial Study Group. J Ocul Pharmacol Ther 2000; 16:3–18
- Acheampong AA, Small D, Baumgarten V, . Formulation effects on ocular absorption of brimonidine in rabbit eyes. J Ocul Pharmacol Ther 2002; 18:325–37
- Dong JQ, Babusis DM, Welty DF, . Effects of the preservative purite on the bioavailability of brimonidine in the aqueous humor of rabbits. J Ocul Pharmacol Ther 2004; 20:285–92
- Ringsdorf L, McGwin Jr G, Owsley C. Visual field defects and vision-specific health-related quality of life in African Americans and whites with glaucoma. J Glaucoma 2006; 15:414–18
- Nelson P, Aspinall P, Papasouliotis O, . Quality of life in glaucoma and its relationship with visual function. J Glaucoma 2003; 12:139–50
- Bauer P, Kieser K. A unifying approach for confidence intervals and testing of equivalence and difference. Biometrika 1996; 83:934–7
- Morikawa T, Yoshida M. A useful testing strategy in phase III trials: combined test of superiority and test of equivalence. J Biopharm Stat 1995; 5:297–306
- Nagasubramanian S, Hitchings RA, Demailly P, . Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study. Ophthalmology 1993; 100:1318–23
- Uusitalo H, Kahonen M, Ropo A, . Improved systemic safety and risk-benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma. Graefes Arch Clin Exp Ophthalmol 2006; 244:1491–96
- Konstas AG, Stewart WC, Topouzis F, . Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. Am J Ophthalmol 2001; 131:729–33